At a glance
This tables includes names and basic information for vaccines available in the U.S.
U.S. Vaccines: Table 1
(For Combination Vaccines, See Table 2)
Vaccine | Trade Name | Abbreviation | Manufacturer | Route | Doses in Routine Series | Approved Ages | Comments |
---|---|---|---|---|---|---|---|
Adenovirus | Adenovirus Type 4 & Type 7 |
Barr Labs Inc. | Oral (2 Tablets) |
1 | 17-50 years | Live: Approved for military populations | |
Anthrax | BioThrax® | AVA | Emergent BioSolutions | IM | 3 | 18-65 years | Inactivated, Adj. |
Cholera | Vaxchora® | PaxVax | Oral (Liquid) | 1 | 18-64 years | Live Attenuated | |
COVID-19 | Comirnaty® | 1vCOV-mRNA | Pfizer | IM | 2 | ≥12 years | mRNA |
SPIKEVAX® | 1vCOV-mRNA | ModernaTx | IM | 2 | ≥18 years | mRNA | |
Dengue | Dengvaxia® | DEN4CYD | Sanofi | SC | 3 | 9-16 years | Live Recombinant |
DTaP | Daptacel® | DTaP | Sanofi | IM | 5 | 6 weeks-6 years | Inactivated, Adj. |
Infanrix® | DTaP | GlaxoSmithKline | IM | 5 | 6 weeks-6 years | Inactivated, Adj. | |
DT | Generic | DT | Sanofi | IM | 5 | 6 weeks-6 years | Inactivated, Adj.: Use when pertussis is contraindicated |
Haemophilus influenzae type b (Hib) | ActHIB® | Hib (PRP-T) | Sanofi | IM | 4 | 2 months-5 years | Inactivated, Adj. (Tetanus toxoid conjugate) |
Hiberix® | Hib (PRP-T) | GlaxoSmithKline | IM | 4 | 6 weeks-4 years | Inactivated, Adj. (Tetanus toxoid conjugate) |
|
PedvaxHIB® | Hib (PRP-OMP) | Merck | IM | 3 | 2-71 months | Inactivated, Adj. (Meningococcal conjugate) |
|
Hepatitis A | Havrix® | HepA | GlaxoSmithKline | IM | 2 | Pediatric: 12 months-18 years Adult: ≥19 years |
Inactivated, Adj. |
Vaqta® | HepA | Merck | IM | 2 | Pediatric: 12 months-18 years Adult: ≥19 years |
Inactivated, Adj. | |
Hepatitis B | Engerix-B® | HepB | GlaxoSmithKline | IM | 3 | Pediatric: Birth-19 years Adult: ≥20 years |
Recombinant, Adj. |
Recombivax HB® | HepB | Merck | IM | 3 | Pediatric: Birth-19 years Adult: ≥20 years |
Recombinant, Adj. | |
Heplisav-B® | HepB | Dynavax Technologies | IM | 2 | ≥18 years | Recombinant, Adj. | |
Herpes Zoster (Shingles) | Shingrix® | RZV | GlaxoSmithKline | IM | 2 | ≥50 years | Recombinant, Adj. |
Human Papillomavirus (HPV) |
Gardasil® 9 | 9vHPV | Merck | IM | 2 or 3 | 9-45 years | Recombinant, Adj. ACIP recommends 9-26 years |
Influenza | Afluria® | IIV3 IIV4 |
Seqirus | IM | 1 or 2 | ≥5 years | Inactivated |
Fluad® | IIV3 | Seqirus | IM | 1 | ≥65 years | Inactivated, Adj. | |
Fluarix® | IIV4 | GlaxoSmithKline | IM | 1 or 2 | ≥6 months | Inactivated | |
Flublok® | RIV4 | Sanofi | IM | 1 | ≥18 years | Recombinant, Egg-Free | |
Flucelvax® | ccIIV4 | Seqirus | IM | 1 or 2 | ≥4 years | Cell-Culture | |
FluLaval® | IIV4 | GlaxoSmithKline | IM | 1 or 2 | ≥6 months | Inactivated | |
FluMist® | LAIV4 | Medimmune | Intranasal | 1 or 2 | 2-49 years | Live Attenuated | |
Fluzone® | IIV3 IIV4 |
Sanofi | IM | 1 or 2 | ≥6 months | Inactivated | |
Fluzone® High-Dose |
IIV3 | Sanofi | IM | 1 | ≥65 years | Inactivated | |
Japanese encephalitis | Ixiaro® | JE | Valneva | IM | 2 | ≥2 months | Inactivated, Adj. |
Measles, Mumps, Rubella | M-M-R® II | MMR | Merck | SC | 2 | ≥12 months | Live Attenuated |
Meningococcal | Menactra® | MCV4 MenACWY-D |
Sanofi | IM | 2 | 9 months-55 years | Inactivated (Diphtheria toxoid conjugate) |
Menveo® | MCV4 MenACWY-CRM |
GlaxoSmithKline | IM | 2 | 2 months-55 years | Inactivated (CRM197 conjugate) |
|
Trumenba® | MenB-FHbp | Pfizer | IM | 2 or 3 | 10-25 years | Recombinant, Adj. | |
Bexsero® | MenB-4C | GlaxoSmithKline | IM | 2 | 10-25 years | Recombinant, Adj. | |
Pneumococcal | Pneumovax® 23 | PPSV23 | Merck | IM or SC | 1 | ≥2 years | Inactivated Polysaccharide |
Prevnar 13® | PCV13 | Pfizer | IM | 4 | ≥6 weeks | Inactivated, Adj. (CRM197 conjugate) |
|
Polio | Ipol® | IPV | Sanofi | IM or SC | 4 | ≥6 weeks | Inactivated |
Rabies | Imovax® Rabies | Sanofi | IM | 3 (pre-exposure) 5 (post-exposure) |
All ages | Inactivated | |
RabAvert® | GlaxoSmithKline | IM | 3 (pre-exposure) 5 (post-exposure) |
All ages | Inactivated | ||
Rotavirus | RotaTeq® | RV5 | Merck | Oral (Liquid) | 3 | 6-32 weeks | Live, Pentavalent |
Rotarix® | RV1 | GlaxoSmithKline | Oral (Liquid) | 2 | 6-24 weeks | Live, Monovalent | |
Tetanus, (reduced) Diphtheria |
Tenivac® | Td | Sanofi | IM | 1 (Every 10 years) | ≥7 years | Inactivated, Adj. |
(Generic) | Td | Massachusetts Biological Labs | IM | 1 (Every 10 years) | ≥7 years | Inactivated, Adj. | |
Tetanus, (reduced) Diphtheria, (reduced) Pertussis |
Boostrix® | Tdap | GlaxoSmithKline | IM | 1 | ≥10 years | Inactivated, Adj. |
Adacel® | Tdap | Sanofi | IM | 1 | 10-64 years | Inactivated, Adj. | |
Typhoid | Typhim Vi® | Sanofi | IM | 1 | ≥2 years | Inactivated, Polysaccharide | |
Vivotif® | PaxVax | Oral (Capsules) | 4 | ≥6 years | Live Attenuated | ||
Varicella | Varivax® | VAR | Merck | SC | 2 | ≥12 months | Live Attenuated |
Vaccinia (Smallpox) | ACAM2000® | Sanofi | Percutaneous | 1 | All ages | Live Attenuated | |
Yellow Fever | YF-Vax® | YF | Sanofi | SC | 1 | ≥9 months | Live Attenuated |
U.S. Vaccines: Table 2
(Combination Vaccines)
Vaccine | Trade Name | Abbreviation | Manufacturer | Route | Doses in Routine Series | Approved Ages | Comments |
---|---|---|---|---|---|---|---|
DTaP, Polio | Kinrix® | DTaP-IPV | GlaxoSmithKline | IM | 1 | 4-6 years | Inactivated, Adj.: Approved as 5th DTaP and 4th IPV. |
Quadracel® | DTaP-IPV | Sanofi | IM | 1 | 4-6 years | Inactivated, Adj.: Approved as 5th DTaP and 4th IPV. | |
DTaP, Hepatitis B, Polio | Pediarix® | DTaP-HepB-IPV | GlaxoSmithKline | IM | 3 | 6 weeks-6 years | Inactivated, Adj.: Approved for 2, 4, 6 month doses. |
DTaP, Polio, Haemophilus influenzae type b | Pentacel® | DTaP-IPV/Hib | Sanofi | IM | 4 | 6 weeks-4 years | Inactivated, Adj.: Approved for 2, 4, 6, 15-18 month doses. |
DTaP, Polio, Haemophilus influenzae type b, Hepatitis B | Vaxelis® | DTap-IPV-Hib-HepB | Sanofi | IM | 3 | 6 weeks-4 years | Recombinant |
Hepatitis A, Hepatitis B | Twinrix® | HepA-HepB | GlaxoSmithKline | IM | 3 | ≥18 years | Inactivated/Recombinant, Adj. Pediatric HepA + Adult HepB |
Measles, Mumps, Rubella, Varicella | ProQuad® | MMRV | Merck | SC | 2 | 12 months- 12 years |
Live Attenuated |
Notes
- The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP. These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the MMWR, the Pink Book, and the American Academy of Pediatrics Red Book, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in which the active components are supplied in their final (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user.
- "Doses in a Routine Series" (Column 6) reflects doses administered to a healthy patient at the recommended ages. It doesn't necessarily reflect schedules for patients with health conditions or other high-risk factors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of doses for that product, and not necessarily the total number of doses in a complete series for the components. (For example, Kinrix® or Quadracel® may be used for only 1 dose of multi-dose DTaP and IPV series.)
- "Adj." in the "Comments" column indicates that the vaccine contains an adjuvant.
- A hyphen in an age range means "through" (i.e., "6 weeks-6 years" means 6 weeks through 6 years [to the 7th birthday]).
Content Source:
National Center for Immunization and Respiratory Diseases